Pharmacology and Clinical Efficacy of Erdosteine in Chronic Obstructive Pulmonary Disease

Maurizio Moretti


Expert Rev Resp Med. 2007;1(3):307-316. 

In This Article


Erdosteine is an original mucoactive molecule, synthesized and developed by Edmond Pharma, and registered in many countries worldwide. There is evidence, both in preclinical and clinical studies, that erdosteine decreases the sputum rheological properties and the daily sputum volume by improving tracheobronchial clearance. Furthermore, erdosteine reduces the bacterial adhesion to mucosal cells and is endowed with local anti-inflammatory activity and a scavenging effect on free oxidant radicals by a direct and indirect antioxidative effect.

In acute exacerbation of CB or COPD, addition of erdosteine to standard treatment significantly modified the outcome by improving the symptoms and reducing the length of disease. In stable COPD patients, the EQUALIFE study demonstrated that erdosteine had a protective effect against exacerbations of COPD: patients treated with erdosteine had 30% fewer exacerbations and 58% fewer days in hospital in the study period. Erdosteine treatment of 8 months significantly improved patients' health status and preserved lung function. The mean total COPD-related disease costs per patient were lower in the erdosteine group than in the placebo group over the study period. These results, together with the drug's safety profile, suggest that erdosteine is likely to provide an important contribution to the therapy of patients with symptomatic COPD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: